摘要
目的:观察血脂水平对瑞舒伐他汀治疗眼睑黄色瘤临床疗效的影响。方法:入选我院2016年1月~2018年2月门诊治疗的眼睑黄色瘤患者52例,根据血脂水平分为高胆固醇血症组34例与胆固醇水平正常的对照组18例,两组均予以瑞舒伐他汀口服,观察治疗12个月后两组眼睑黄色瘤及血脂水平改变,并进行组间对比。结果:两组血脂水平中总胆固醇及低密度脂蛋白水平均较治疗前明显降低,高胆固醇血症组较对照组进一步降低,且具有显著差异(P<0.05)。两组眼睑黄色瘤经治疗均有明显改善,两组比较无显著差异(P>0.05)。结论:眼睑黄色瘤无论是否合并高胆固醇血症,瑞舒伐他汀均可达到良好的临床治疗效果。
Objective:To observe the effect of blood lipid level on the clinical efficacy of rosuvastatin in patients with orbital xanthoma.Methods:52 patients with orbital xanthoma treated in our hospital from January 2016 to February 2018 were enrolled in the hospital.According to the blood lipid level,34 patients in the hypercholesterolemia group and 18 patients in the control group with normal cholesterol levels were enrolled.Rosuvarastatin was taken orally.The changes of orbital xanthomas and blood lipid levels in the two groups were observed after 12 months of treatment.Results:The levels of total cholesterol and low-density lipoprotein in blood lipid levels of the two groups were significantly lower than those before treatment,and the hypercholesterolemia group was further reduced compared with the control group,and there was statistical difference(P<0.05).The eyelid xanthoma of the two groups were significantly improved after treatment.There was no significant difference between the two groups(P>0.05).Conclusions:For patients with orbital xanthomas,rosuvastatin can achieve good clinical results regardless of hypercholesterolemia.
作者
陆寅
李跃
Lu Yin;Li Yue(Department of Ophthalmology,Nanyuan hospital,Beijing,Fengtai District,100076,China)
出处
《北方药学》
2019年第12期134-135,共2页
Journal of North Pharmacy
